In a report released today, Swayampakula Ramakanth from H.C. Wainwright maintained a Buy rating on ImmunoPrecise Antibodies, with a price target of $5.00.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Swayampakula Ramakanth has given his Buy rating due to a combination of factors that highlight ImmunoPrecise Antibodies’ growth potential and financial performance. The company’s AI segment, particularly through BioStrand, is expected to significantly boost revenues and margins. BioStrand’s contribution to total revenues increased from less than 2% to over 5% year-over-year, and further growth is anticipated as new AI-related collaborations are set to generate additional income.
Moreover, the AI business is experiencing a rapid expansion, with projections indicating a 26% year-over-year increase in total revenues for FY26. The gross margin has also shown substantial improvement, reaching 64% in 4QFY25, and is expected to continue rising as the AI segment grows. Despite the divestiture of a Dutch facility, the core business remains robust, with Canadian operations showing strong growth. These factors collectively support the Buy rating, indicating a positive outlook for the company’s financial future.